(Q51595759)

7 April 2018

title

Suppression of non-esterified fatty acids to treat type A insulin resistance syndrome. (English)

1 reference

7 April 2018

1 reference

S Kumar

1

1 reference

7 April 2018

P N Durrington

series ordinal

2

1 reference

7 April 2018

D Bhatnagar

series ordinal

3

1 reference

7 April 2018

I Laing

series ordinal

4

1 reference

7 April 2018

language of work or name

English

0 references

publication date

1 April 1994

1 reference

7 April 2018

published in

The Lancet

1 reference

7 April 2018

volume

343

1 reference

7 April 2018

issue

8905

1 reference

7 April 2018

page(s)

1073-1074

1 reference

7 April 2018

The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990184-8

7 January 2021

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990184-8

7 January 2021

Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990184-8

7 January 2021

Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990184-8

7 January 2021

Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990184-8

7 January 2021

A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990184-8

7 January 2021

The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990184-8

7 January 2021

10.1016/S0140-6736(94)90184-8

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

7909102

1 reference

7 April 2018